Anti-Human CD22 Therapeutic Antibody scFv Fragment (hLL2)

The anti-CD22 Antibody-Drug Conjugates comprise a drug moiety, an anti-CD22 antibody and a hydrophilic self-immolative linker. The antibody in this ADC compound specifically target human cluster of differentiation-22, which belongs to the SIGLEC family of lections. Therefore the anti-CD22 ADC compound can be used in the treatment or diagnosis of hematological malignancy.
Supplier Creative Biolabs
Product # TAB-0196CL-S(P)
Pricing Inquiry
Host Human
Target CD22
Feedback